PharmTech’s Regulatory Roundup for May 2026: Drug Approvals
Decision brief
Answer first · skim in under a minute
PharmTech's May 2026 Regulatory Roundup highlights significant drug approvals and their potential impact on the pharmaceutical landscape. This article provides insights for business development teams, investors, and analysts.
PharmTech's Regulatory Roundup for May 2026: Drug Approvals should start from the FDA record, not rumor. In May 2026 the agency cleared Veppanu, Bizengri, and Beqalzi among other novel therapies, with dated labels, trial IDs, and response metrics that BD and investor teams can verify.
Contents10 sections
Key Takeaways
- On May 1, 2026, FDA approved vepdegestrant (Veppanu, Arvinas) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy.
- On May 8, 2026, FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive advanced cholangiocarcinoma under the Commissioner's National Priority Review Voucher pilot.
- On May 13, 2026, FDA granted accelerated approval to sonrotoclax (Beqalzi) for relapsed or refractory mantle cell lymphoma after at least two prior systemic lines including a BTK inhibitor.
- FDA's 2026 novel-drug table also lists Baxfendy (baxdrostat) on May 15, 2026 for hypertension used with other antihypertensives.
Which May 2026 FDA approvals actually cleared?
The fabricated names sometimes circulating in secondary roundups do not appear on FDA's novel-drug table. The dated May 2026 novel approvals that do appear include Veppanu (May 1), Beqalzi (May 13), and Baxfendy (May 15), with additional indication and rare-disease actions such as Bizengri on May 8.
FDA publishes the running list at its Novel Drug Approvals for 2026 page. Teams should treat that table, plus the matching Drugs@FDA label pages, as the primary chronology for any May regulatory roundup.
Later May novel entries on the same table include Hepcludex (bulevirtide-gmod) on May 22, Decnupaz on May 27, and three May 29 clearances (Zaynich, Xocova, and Cypsedo).
What did FDA approve with Veppanu on May 1, 2026?
On May 1, 2026, FDA approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer detected by an FDA-authorized test, after progression following at least one line of endocrine therapy.
According to the FDA approval notice, the agency also cleared Guardant360 CDx as a companion diagnostic for ESR1 mutations. Efficacy was evaluated in VERITAC-2 (NCT05654623), a randomized open-label trial in 624 adults, including 270 with ESR1-mutated tumors.
Patients had progressed on one to two endocrine lines, including a CDK4/6 inhibitor line, and were randomized 1:1 to oral vepdegestrant once daily or intramuscular fulvestrant. The major efficacy endpoint was progression-free survival by blinded independent central review.
Why does Bizengri matter for rare bile duct cancer?
On May 8, 2026, FDA approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy.
The FDA Bizengri notice states the application ran under the Commissioner's National Priority Review Voucher pilot and finished more than five months ahead of the goal date. Safety and efficacy came from the eNRGy trial (NCT02912949).
Among 19 efficacy-evaluable patients with NRG1 fusion-positive cholangiocarcinoma, confirmed overall response rate was 36.8% (95% CI: 16.3, 61.6), with duration of response ranging from 2.8 to 12.9 months. For deeper coverage of the priority-review angle, see NovaPharma's Bizengri national priority report.
How strong was the Beqalzi mantle cell lymphoma package?
On May 13, 2026, FDA granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma after at least two systemic lines including a BTK inhibitor.
The FDA Beqalzi notice cites BGB-11417-201 (NCT05471843), a single-arm multicenter study in 103 adults previously treated with anti-CD20 therapy and a BTK inhibitor.
Independent review using Lugano criteria showed an overall response rate of 52% (95% CI: 42, 62), median time to response of 1.9 months, and median duration of response of 15.8 months (95% CI: 7.4, not estimable) after about 11.9 months median follow-up. Label warnings include tumor lysis syndrome and serious infections.
What else landed on the May 2026 novel-drug table?
Beyond the oncology clearances above, FDA's novel-drug table lists Baxfendy (baxdrostat) on May 15, 2026 to treat hypertension in combination with other antihypertensive drugs.
Later May novel approvals on the same FDA table include Hepcludex (bulevirtide-gmod) on May 22 for chronic hepatitis delta, Decnupaz (pivekimab sunirine-pvzy) on May 27 for blastic plasmacytoid dendritic cell neoplasm, and three May 29 products: Zaynich (cefepime and zidebactam), Xocova (ensitrelvir), and Cypsedo (cipepofol).
That breadth matters for portfolio screening: May was not only an oncology month. Cardiovascular, antiviral, anti-infective, and anesthesia assets also crossed the novel-drug line.
What should BD and investor teams do next?
Map each May clearance to a commercial question rather than a headline. For Veppanu, watch ESR1 testing uptake and fulvestrant share shifts. For Bizengri, watch NRG1 fusion testing rates in cholangiocarcinoma referrals. For Beqalzi, watch how post-BTK MCL sequencing competes with other BCL-2 and cellular options.
Cross-check manufacturing and evidence readiness against NovaPharma's manufacturing pipeline approvals evidence brief and broader pipeline catalysts such as the Sanofi 2026 catalysts note.
Do not treat secondary roundups that invent brand names as sources. If a claimed May approval is absent from FDA's novel-drug table and Drugs@FDA, delete it from diligence memos.
Related NovaPharma coverage
- Bizengri FDA national priority nod for rare bile duct cancer
- Manufacturing pipeline approvals: what the evidence confirms
- FDA approves Vertex Journavx for acute pain
Frequently Asked Questions
Which novel FDA drugs were approved in early May 2026?
FDA approved vepdegestrant (Veppanu) on May 1, 2026, zenocutuzumab-zbco (Bizengri) on May 8, 2026, and granted accelerated approval to sonrotoclax (Beqalzi) on May 13, 2026.
What trial supported the May 2026 Veppanu approval?
Efficacy for Veppanu was evaluated in VERITAC-2 (NCT05654623), a randomized trial in 624 adults with ER-positive, HER2-negative advanced or metastatic breast cancer, including 270 with ESR1 mutations.
What response rate did Beqalzi show in mantle cell lymphoma?
In BGB-11417-201 (NCT05471843), overall response rate was 52% (95% CI: 42, 62) among adults with relapsed or refractory mantle cell lymphoma after anti-CD20 therapy and a BTK inhibitor.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
